Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
出版年份 2019 全文链接
标题
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
作者
关键词
Non-small cell lung cancer, Oncology, Programmed cell death protein-1, Programmed cell death ligand 1, Inhibitor, Immune-related adverse event, Meta-analysis, Systematic review
出版物
BMC CANCER
Volume 19, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-06-10
DOI
10.1186/s12885-019-5701-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Systematic reviews and cancer research: a suggested stepwise approach
- (2018) George A. Kelley et al. BMC CANCER
- Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
- (2018) David Waterhouse et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
- (2018) Christophoros Astaras et al. Current Neurology and Neuroscience Reports
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
- (2018) Wei You et al. Journal of Cancer
- Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios
- (2018) Rebecca Tay et al. Journal of Thoracic Disease
- SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy
- (2018) C E Higham et al. Endocrine Connections
- Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
- (2018) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048
- (2018) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
- (2017) D. Makarious et al. EUROPEAN JOURNAL OF CANCER
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- (2017) Solange Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
- (2017) Clélia Coutzac et al. Journal of Crohns & Colitis
- Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab
- (2017) Daniel R. Matson et al. JOURNAL OF FORENSIC SCIENCES
- Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
- (2017) Hong Li et al. Journal of Hematology & Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma
- (2017) Yu-Hsiu Chen et al. MEDICINE
- Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer
- (2017) Xiaoying Sun et al. MEDICINE
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
- (2017) Peng-Fei Wang et al. Frontiers in Pharmacology
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
- (2017) James Luke Godwin et al. Journal for ImmunoTherapy of Cancer
- Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade
- (2017) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes
- (2016) Sung Hye Kong et al. ACTA DIABETOLOGICA
- Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
- (2016) Anushree C. Shirali et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion
- (2016) Igal Kushnir et al. CARDIOLOGY
- Pericardial effusion with tamponade physiology induced by nivolumab
- (2016) Jennifer Nesfeder et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
- (2016) Kurt B. Schaberg et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)
- (2016) Puey Ling Chia et al. JOURNAL OF IMMUNOTHERAPY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma
- (2016) V. Gounant et al. LUNG CANCER
- Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab
- (2016) Samer Tabchi et al. LUNG CANCER
- Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report
- (2016) Kazuhiko Ikeuchi et al. LUNG CANCER
- Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung
- (2016) H. Semper et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
- (2016) M. Nishino et al. Cancer Immunology Research
- Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
- (2016) J. Naidoo et al. Cancer Immunology Research
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
- (2015) Steven Orlov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
- (2015) R. Stewart et al. Cancer Immunology Research
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
- A basic introduction to fixed-effect and random-effects models for meta-analysis
- (2010) Michael Borenstein et al. Research Synthesis Methods
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started